Unmet needs for migraine

References

• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
   PubMed Web of Science ®Google Scholar
• De Matteis E, Guglielmetti M, Ornello R, et al. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020;20(6):627–641. PMID: 32434430.
   PubMed Web of Science ®Google Scholar
• Capi M, De Angelis V, De Bernardini D, et al. CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine. J Clin Med. 2021;10(7):1429.
   PubMed Web of Science ®Google Scholar
• Curto M, Capi M, Cipolla F, et al. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;21(7):755–759. Epub 2020 Feb 3. PMID: 32011192.
   PubMed Web of Science ®Google Scholar
• Spuntarelli V, Negro A, Luciani M, et al. Eptinezumab for the treatment of migraine. Expert Opin Biol Ther. 2021;21(8):999–913. Epub ahead of print. PMID: 34009094.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Novel synthetic treatment options for migraine. Expert Opin Pharmacother. 2021;22(7):907–922. PMID: 33369482.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Rimegepant for the treatment of migraine. Drugs Today. 2020;56(12):769–780. PMID: 33332483.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. Erratum in: Lancet. 2020;396(10262):1562.
   PubMed Web of Science ®Google Scholar
• D’Amico D, Tepper SJ, Guastafierro E, et al. Mapping assessments instruments for headache disorders against the ICF biopsychosocial model of health and disability. Int J Environ Res Public Health. 2020;18(1):246.
   Web of Science ®Google Scholar
• Leonardi M, Grazzi L, D’Amico D, et al. Global burden of headache disorders in children and adolescents 2007–2017. Int J Environ Res Public Health. 2020;18(1):250.
   Web of Science ®Google Scholar
• Kim BK, Chu MK, Yu SJ, et al. Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021;22(1):45. Erratum in: J Headache Pain. 2021;22(1):56.
   PubMed Web of Science ®Google Scholar
• Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111.
   PubMed Web of Science ®Google Scholar
• Kikui S, Chen Y, Todaka H, et al. Burden of migraine among japanese patients: a cross-sectional national health and wellness Survey. J Headache Pain. 2020;21(1):110.
   PubMed Web of Science ®Google Scholar
• Wong LP, Alias H, Bhoo-Pathy N, et al. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain. 2020;21(1):68. Erratum in: J Headache Pain. 2020;21(1):104.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in Triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying migraine drugs (DMMDs)). J Headache Pain. 2019;20(1):60.
   PubMed Web of Science ®Google Scholar
• Sussman M, Benner J, Neumann P, et al. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644–1657. PMID: 30142988.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Costantini R, et al. Acute headache management in emergency department: a narrative review. Intern Emerg Med. 2020;15(1):109–117. PMID: 31893348.
   PubMed Web of Science ®Google Scholar
• Negro A, Spuntarelli V, Sciattella P, et al. Rapid referral for headache management from emergency department to headache Centre: four years data. J Headache Pain. 2020;21(1):25.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Vo P, et al. Healthcare resource use and indirect costs associated with migraine in Italy: results from the My migraine voice survey. J Med Econ. 2021;24(1):717–726.
   PubMed Web of Science ®Google Scholar
• Negro A, Sciattella P, Rossi D, et al. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120.
   PubMed Web of Science ®Google Scholar
• Sacco S, Lampl C, Maassen van den Brink A, et al. Burden and attitude to resistant and refractory migraine: a survey from the european headache federation with the endorsement of the european migraine & headache Alliance. J Headache Pain. 2021;22(1):39.
   PubMed Web of Science ®Google Scholar
• Dresler T, Caratozzolo S, Guldolf K, et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019;20(1):51.
   PubMed Web of Science ®Google Scholar
• Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs. 2017;31(6):483–485. PMID: 29124668.
   PubMed Web of Science ®Google Scholar
• Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–514. PMID: 34145431.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Aug 9]. Available from: https://web.uniroma1.it/masterheadache/.
   Google Scholar
• [cited 2021 Aug 9]. Available from: https://mhd.ku.dk.
   Google Scholar
• Schytz HW, Amin FM, Jensen RH, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. J Headache Pain. 2021;22(1):22.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Tinelli M. Editorial. Valuing headache’s solution. J Headache Pain. 2021;22(1):54.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716–1725.
   PubMed Web of Science ®Google Scholar